CLAIMS:-

1. A *Streptococcus pneumoniae* immunogenic composition comprising 10 or more capsular saccharides from different *S. pneumoniae* serotypes which are conjugated to a carrier protein, and comprising 3 or more different carrier proteins, wherein the composition comprises:
   serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT);
   serotype 18C capsular saccharide conjugated to tetanus toxoid (TT);
   serotype 1, 4, 5, 6B, 7F, 9V, 14 and 23F capsular saccharides conjugated to protein D from *Haemophilus influenzae*.

2. An immunogenic composition according to claim 1 wherein 19F capsular saccharide is directly conjugated to the carrier protein.

3. An immunogenic composition according to claim 1 wherein 19F capsular saccharide is conjugated to the carrier protein via a linker.

4. An immunogenic composition according to claim 3 wherein the linker is bifunctional.

5. The immunogenic composition of claim 3 or claim 4 wherein the linker is ADH.

6. The immunogenic composition of any one of claims 3 to 5, wherein the linker is attached to the carrier protein by carbodiimide chemistry, or using EDAC chemistry.

7. The immunogenic composition of any preceding claim wherein the 19F saccharide is conjugated to the carrier protein or to the linker using CDAP chemistry.

8. The immunogenic composition of any preceding claim wherein the ratio of carrier protein to 19F saccharide is between 5:1 and 1:5, 4:1 and 1:1 or 2:1 and 1:1, or 1.5:1 and 1.4:1 (w/w).

9. The immunogenic composition of any preceding claim wherein the average size (e.g. M_w) of the 19F saccharide is above 100 kDa.

10. The immunogenic composition of any preceding claim wherein the dose of the 19F saccharide conjugate is between 1 and 10 μg, 1 and 5 μg, or 1 and 3 μg of saccharide.

11. An immunogenic composition according to any preceding claim further comprising serotype 6A and/or 15B.

12. An immunogenic composition according to any preceding claim further comprising serotype 19A.

13. An immunogenic composition according to any preceding claim further comprising serotype 22F.

14. An immunogenic composition according to any preceding claim which comprises pneumolysin as free or carrier protein.

15. An immunogenic composition according to any preceding claim which comprises a PhtX protein, PhtD protein, a PhtBD fusion protein or a PhtDE fusion protein as free or carrier protein.

16. Use of *Streptococcus pneumoniae* immunogenic compositions comprising 9 or more, 10 or more, 11 of more, 13 or more, or 14 or more capsular saccharides from different *S.pneumoniae* serotypes conjugated to 2 or more different carrier proteins, wherein the composition comprises serotype 19F capsular saccharide conjugated to CRM197 using CDAP chemistry, but does not comprise capsular saccharide from serotype 19A in the preparation of a medicament for the treatment or prevention of a disease caused by *Streptococcus pneumoniae* serotype 19A strain infection.

CLAIMS

1. A *Streptococcus pneumoniae* immunogenic composition comprising 9 or more, 10 or more, 11 or more, 13 or more, or 14 or more capsular saccharides from different *S. pneumoniae* serotypes conjugated to 2 or more different carrier proteins, wherein the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197
2. An immunogenic composition according to claim 1 wherein serotype 19F is conjugated to Diphtheria toxoid.
3. An immunogenic composition according to claim 1 or 2 wherein said composition further comprises protein D from *Haemophilus influenzae*.
4. An immunogenic composition according to any preceding claim wherein 19F capsular saccharide is directly conjugated to the carrier protein.
5. An immunogenic composition according to any of claims 1 to 3 wherein 19F capsular saccharide is conjugated to the carrier protein via a linker.
6. An immunogenic composition according to claim 5 wherein the linker is bifunctional.
7. The immunogenic composition of claim 5 or 6 wherein the linker is ADH.
8. The immunogenic composition of claims 5, 6, or 7 wherein the linker is attached to the carrier protein by carbodiimide chemistry, preferably using EDAC.
9. The immunogenic composition of any of claims 5 to 8 wherein the saccharide is conjugated to the linker before the carrier protein is conjugated to the linker.
10. The immunogenic composition of any of claims 5 to 8 wherein the carrier protein is conjugated to the linker before the saccharide is conjugated to the linker.
11. the immunogenic composition of any preceding claim wherein the 19F saccharide is conjugated to the carrier protein or to the linker using CDAP chemistry.
12. The immunogenic composition of any preceding claim wherein the ratio of carrier protein to 19F saccharide is between 5:1 and 1:5, 4:1 and 1:1 or 2:1 and 1:1, or 1.5:1 and 1.4:1 (w/w).
13. The immunogenic composition of any preceding claim wherein the average size (e.g. M_w) of the 19F saccharide is above 100 kDa.
14. The immunogenic composition of claim 13 wherein the average size (e.g. M_w) of the 19F saccharide is between 100-750, 110-500, 120-250, or 125 and 150 kDa.

15. The immunogenic composition of claim 13 or 14 wherein the 19F saccharide is either a native polysaccharide or is sized by a factor of no more than x5.

16. The immunogenic composition of claim 13, 14 or 15 wherein the 19F saccharide has been sized by microfluidization.

17. The immunogenic composition of any preceding claim wherein the dose of the 19F saccharide conjugate is between 1 and 10 µg, 1 and 5 µg, or 1 and 3 µg of saccharide.

18. An immunogenic composition according to any preceding claim wherein at least 8 of the capsular saccharides are conjugated to the same carrier protein.

19. An immunogenic composition according to claim 18 wherein said carrier protein is not diphtheria toxoid and/or is not CRM197.

20. An immunogenic composition according to any preceding claim comprising 2 different carrier proteins.

21. An immunogenic composition according to any preceding claim comprising 3, 4, 5 or 6 different carrier proteins.

22. An immunogenic composition according to any preceding claim wherein one or more or all carrier proteins is selected from the group consisting of DT, CRM 197, TT, Fragment C, dPly, PhtA, PhyB, PhtD, PhtE, PhtDE OmpC, PorB and *Haemophilus influenzae* Protein D.

23. An immunogenic composition according to claim 22 wherein one carrier protein is protein D.

24. An immunogenic composition according to claim 22 wherein one carrier protein is TT.

25. An immunogenic composition according to any of claims 22, 23 or 24 wherein both TT and protein D are present as carrier proteins.

26. An immunogenic composition according to any of claims 22, 23, 24 or 25 wherein at least 8 of the capsular saccharides are conjugated to protein D.

27. An immunogenic composition according to any preceding claim wherein the composition comprises capsular saccharide 18C conjugated to TT, optionally wherein 18C is the only saccharide in the composition conjugated to tetanus toxoid (TT).

28. An immunogenic composition according to any preceding claim wherein 18C capsular saccharide is directly conjugated to the carrier protein.

29. An immunogenic composition according to any of claims 1 to 27 wherein 18C capsular saccharide is conjugated to the carrier protein via a linker.

30. An immunogenic composition according to claim 29 wherein the linker is bifunctional.

31. The immunogenic composition of claim 29 or 30 wherein the linker is ADH.

32. The immunogenic composition of claims 29, 30, or 31 wherein the linker is attached to the carrier protein by carbodiimide chemistry, preferably using EDAC.

33. The immunogenic composition of any of claims 29 to 31 wherein the saccharide is conjugated to the linker before the carrier protein is conjugated to the linker.

34. The immunogenic composition of any of claims 29 to 31 wherein the carrier protein is conjugated to the linker before the saccharide is conjugated to the linker.

35. the immunogenic composition of any preceding claim wherein the 18C saccharide is conjugated to the carrier protein or linker using CDAP chemistry.

36. The immunogenic composition of any preceding claim wherein the 18C saccharide is conjugated to the carrier protein or linker using reductive amination.

37. The immunogenic composition of any preceding claim wherein the ratio of carrier protein to 18C saccharide is between 0.5:1-5:1, 1:1-4:1, 1.5:1-3:1, or 2:1 and 2.5:1 (w/w).

38. The immunogenic composition of any preceding claim wherein the average size (e.g. M_w) of the 18C saccharide is above 50 kDa.

39. The immunogenic composition of claim 38 wherein the average size (e.g. M_w) of the 18C saccharide is between 50-500, 60-400, 70-300, 75-200, or 80 and 100 kDa.

40. The immunogenic composition of claim 39 wherein the 18C saccharide is either a native polysaccharide or is sized by a factor of no more than x5.

41. The immunogenic composition of claim 38, 39 or 40 wherein the 18C saccharide has been sized by microfluidization.

42. The immunogenic composition of any preceding claim wherein the dose of the 18C saccharide conjugate is between 1 and 10 µg, 1 and 5 µg, or 1 and 3 µg of saccharide.

43. The immunogenic composition of claim 42 wherein the dose of the 18C saccharide conjugate is 3 µg of saccharide.

44. An immunogenic composition according to any preceding claim wherein a capsular saccharide conjugate of serotype 6B is present, but is not conjugated to DT and/or CRM197.

45. An immunogenic composition according to any preceding claim wherein a capsular saccharide conjugate of serotype 23F is present, but is not conjugated to DT and/or CRM197.

46. An immunogenic composition according to any preceding claim wherein at least serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F are present as conjugated saccharides.

47. An immunogenic composition according to any preceding claim wherein serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F are present and are all conjugated to protein D.

48. An immunogenic composition according to any preceding claim further comprising serotype 3 present as a conjugated saccharide.

49. An immunogenic composition according to claim 48 wherein serotype 3 is conjugated to protein D.

50. An immunogenic composition according to any preceding claim further comprising (conjugated capsular saccharide of) serotype 6A and/or 15B.

51. An immunogenic composition according to any preceding claim further comprising (conjugated capsular saccharide of) serotype 19A.

52. An immunogenic composition according to any preceding claim further comprising (conjugated capsular saccharide of) serotype 22F.

53. An immunogenic composition according to any preceding claim further comprising (conjugated capsular saccharide of) serotype 8.

54. An immunogenic composition according to any preceding claim further comprising (conjugated capsular saccharide of) serotype 12F.

55. An immunogenic composition according to any preceding claim wherein at least one of the capsular saccharides is directly conjugated to the carrier protein.

56. An immunogenic composition according to any preceding claim wherein at least one of the capsular saccharides is conjugated to the carrier protein via a linker.

57. An immunogenic composition according to claim 56 wherein the linker is bi-functional.

58. The immunogenic composition of claim 56 or 57 wherein the linker is ADH.

59. The immunogenic composition of claims 56, 57, or 58 wherein the linker is attached to the carrier protein by carbodiimide chemistry, preferably using EDAC.

60. The immunogenic composition of any of claims 56 to 59 wherein the saccharide is conjugated to the linker before the carrier protein is conjugated to the linker.

61. The immunogenic composition of any of claims 56 to 59 wherein the carrier protein is conjugated to the linker before the saccharide is conjugated to the linker.

62. The immunogenic composition of any preceding claim wherein at least one of the capsular saccharides is conjugated to the carrier protein and/or linker using CDAP chemistry.

63. The immunogenic composition of any preceding claim wherein at least one of the capsular saccharides is conjugated to the carrier protein and/or linker using reductive amination.

64. The immunogenic composition of claim 63 wherein capsular saccharide 3 is conjugated to the carrier protein and/or linker using reductive amination.

65. The immunogenic composition of claim 63 or 64 wherein capsular saccharide 1 is conjugated to the carrier protein and/or linker using reductive amination.

66. The immunogenic composition of any preceding claim wherein the ratio of carrier protein to saccharides is between 0.5:1-5:1, 1:2 and 2.5:1, 1:1-3.5:1, or 1.3:1-3.0:1.

67. The immunogenic composition of any preceding claim wherein the average size (e.g. M_w) of the saccharides (in the saccharide conjugates) is above 50 kDa, e.g, 50-1600, 80-1400, 100-1000, 150-500, or 200-400 kDa.

68. The immunogenic composition of any preceding claim which comprises serotype 1 (saccharide conjugate) having an average saccharide size (e.g. M_w) of between 100-1000, 200-800, 250-600, or 300 and 400 kDa.

69. The immunogenic composition of any preceding claim which comprises serotype 4 (saccharide conjugate) having an average saccharide size (e.g. M_w) of between 50-500, 60-300, 70-200, or 75 and 125 kDa.

70. The immunogenic composition of any preceding claim which comprises serotype 5 (saccharide conjugate) having an average saccharide size (e.g. M_w) of between 100-1000, 200-700, 300-500, or 350 and 450 kDa.

71. The immunogenic composition of any preceding claim which comprises serotype 6B (saccharide conjugate) having an average saccharide size (e.g. M_w) of between 500-1600, 750-1500, or 1000 and 1400 kDa.

72. The immunogenic composition of any preceding claim which comprises serotype 7F (saccharide conjugate) having an average saccharide size (e.g. M_w) of between 50-1000, 100-750, 150-500, or 200 and 300 kDa.

73. The immunogenic composition of any preceding claim which comprises serotype 9V (saccharide conjugate) having an average saccharide size (e.g. M_w) of between 50-1000, 100-750, 150-500, 200-400, or 250 and 300 kDa.

74. The immunogenic composition of any preceding claim which comprises serotype 14 (saccharide conjugate) having an average saccharide size (e.g. M_w) of between 50-1000, 100-750, 150-500, or 200 and 250 kDa.

75. The immunogenic composition of any preceding claim which comprises serotype 23F (saccharide conjugate) having an average saccharide size (e.g. M_w) of between 500-1500, 700-1300, 800-1100, or 900 and 1000 kDa.

76. The immunogenic composition of any preceding claim which comprises serotype 19A (saccharide conjugate) having an average saccharide size (e.g. M_w) of between 50 and 800kDa, 110 and 700 kDa, 110-300, 120-200, 130-180, or 140-160 kDa.

77. The immunogenic composition of any preceding claim which comprises serotype 22F (saccharide conjugate) having an average saccharide size (e.g. M_w) of between 50 and 800 kDa, 110 and 700 kDa, 110-300, 120-200, 130-180, or 150-170 kDa.

78. The immunogenic composition of any preceding claim which comprises serotype 6A (saccharide conjugate) having an average saccharide size (e.g. M_w) of between 500 and 1600 kDa, or 1100 and 1540 kDa.

79. The immunogenic composition of any preceding claim which comprises serotype 3 (saccharide conjugate) having an average saccharide size (e.g. M_w) of between 50 and 1000 kDa, 60 and 800, 70 and 600, 80 and 400, 100 and 300, or 150 and 250 kDa.

80. The immunogenic composition of any preceding claim which comprises serotypes 5, 6B and 23F as native saccharides.

81. The immunogenic composition of any preceding claim wherein the dose of the capsular saccharide conjugates is between 1 and 10 µg, 1 and 5 µg, or 1 and 3 µg of saccharide per conjugate.

82. The immunogenic composition of any preceding claim which comprises conjugates of serotypes 4, 18C and 19F at dosages of 3 µg of saccharide per conjugate.

83. The immunogenic composition of any preceding claim which comprises conjugates of serotypes 1, 5, 6B, 7F, 9V, 14 and 23F at dosages of 1 µg of saccharide per conjugate.

84. The immunogenic composition of any preceding claim which comprises conjugates of serotypes 6A and/or 3 at dosages of 1 µg of saccharide per conjugate.

85. The immunogenic composition of any preceding claim which comprises conjugates of serotypes 19A and/or 22F at dosages of 3 µg of saccharide per conjugate.

86. The immunogenic composition of any preceding claim which further comprises unconjugated *S. pneumoniae* saccharides of serotypes different from those conjugated, such that the number of conjugated and unconjugated saccharide serotypes is less than or equal to 23.

87. The immunogenic composition of any preceding claim which further comprises one or more unconjugated or conjugated *S pneumoniae* proteins.

88. The immunogenic composition of claim 87 which comprises one or more unconjugated *S. pneumoniae* proteins.

89. The immunogenic composition of claim 87 or 88 wherein said one or more *S. pneumoniae* proteins are selected from Poly Histidine Triad family (PhtX), Choline Binding Protein family (CbpX), CbpX truncates, LytX family,

~~LytX truncates, CbpX truncate-LytX truncate chimeric proteins, detoxified~~ pneumolysin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 and Sp133.

90. The immunogenic composition of claims 87, 88 or 89 which comprises pneumolysin.

91. The immunogenic composition of any of claims 87 to 90 which comprises a PhtX protein.

92. An immunogenic composition according to any preceding claim which comprises pneumolysin as free or carrier protein.

93. An immunogenic composition according to any preceding claim which comprises a PhtX protein as free or carrier protein.

94. The immunogenic composition of claim 93 wherein said PhtX protein is PhtD or a PhtBD or PhtDE fusion protein.

95. A immunogenic composition according to any preceding claim which further comprises an adjuvant.

96. An immunogenic composition according to claim 95 wherein the adjuvant is a preferential inducer of a Th1 response.

97. An immunogenic composition according to claim 95 or 96 wherein the adjuvant comprises one or more components selected from QS21, MPL® or an immunostimulatory oligonucleotide.

98. An immunogenic composition according to any of claims 95 to 97 wherein the adjuvant comprises QS21 and MPL.

99. The immunogenic composition of claim 95, wherein the adjuvant comprises a liposome carrier.

100. The immunogenic composition of claim 99, wherein the adjuvant comprises (per 0.5 mL dose) 0.1-10mg, 0.2-7, 0.3-5, 0.4-2, or 0.5-1 mg (e.g. 0.4-0.6, 0.9-1.1, 0.5 or 1 mg) phospholipid (for instance DOPC).

101. The immunogenic composition of claim 99 or 100, wherein the adjuvant comprises (per 0.5 mL dose) 0.025-2.5, 0.05-1.5, 0.075-0.75, 0.1-0.3, or 0.125-0.25 mg (e.g. 0.2-0.3, 0.1-0.15, 0.25 or 0.125 mg) sterol (for instance cholesterol).

102. The immunogenic composition of claims 99-101, wherein the adjuvant comprises (per 0.5 mL dose) 5-60, 10-50, or 20-30 µg (e.g. 5-15, 40-50, 10, 20, 30, 40 or 50 µg) lipid A derivative (for instance 3D-MPL).

103. The immunogenic composition of claims 99-102, wherein the adjuvant comprises (per 0.5 mL dose) 5-60, 10-50, or 20-30 µg (e.g. 5-15, 40-50, 10, 20, 30, 40 or 50 µg) saponin (for instance QS21).

104. The immunogenic composition of claim 95, wherein the adjuvant comprises an oil in water emulsion.

105. The immunogenic composition of claim 104, wherein the adjuvant comprises (per 0.5 mL dose) 0.5-15, 1-13, 2-11, 4-8, or 5-6mg (e.g. 2-3, 5-6, or 10-11 mg) metabolisable oil (such as squalene).

106. The immunogenic composition of claim 104 or 105, wherein the adjuvant comprises (per 0.5 mL dose) 0.1-10, 0.3-8, 0.6-6, 0.9-5, 1-4, or 2-3 mg (e.g. 0.9-1.1, 2-3 or 4-5 mg) emulsifier (such as Tween 80).

107. The immunogenic composition of claims 104-106, wherein the adjuvant comprises (per 0.5 mL dose) 0.5-20, 1-15, 2-12, 4-10, 5-7 mg (e.g. 11-13, 5-6, or 2-3 mg) tocol (such as alpha tocopherol).

108. The immunogenic composition of claims 104-107, wherein the adjuvant comprises (per 0.5 mL dose) 5-60, 10-50, or 20-30 μg (e.g. 5-15, 40-50, 10, 20, 30, 40 or 50 μg) lipid A derivative (for instance 3D-MPL).

109. The immunogenic composition of claims 104-108, wherein the adjuvant comprises (per 0.5 mL dose) 0.025-2.5, 0.05-1.5, 0.075-0.75, 0.1-0.3, or 0.125-0.25 mg (e.g. 0.2-0.3, 0.1-0.15, 0.25 or 0.125 mg) sterol (for instance cholesterol).

110. The immunogenic composition of claims 104-109, wherein the adjuvant comprises (per 0.5 mL dose) 5-60, 10-50, or 20-30 μg (e.g. 5-15, 40-50, 10, 20, 30, 40 or 50 μg) saponin (for instance QS21).

111. The immunogenic composition of claim 95, wherein the adjuvant comprises a metal salt and lipid A derivative.

112. The immunogenic composition of claim 111, wherein the adjuvant comprises (per 0.5 mL dose) 100-750, 200-500, or 300-400 μg Al as aluminium phosphate.

113. The immunogenic composition of claim 111 or 112, wherein the adjuvant comprises (per 0.5 mL dose) 5-60, 10-50, or 20-30 μg (e.g. 5-15, 40-50, 10, 20, 30, 40 or 50 μg) lipid A derivative (for instance 3D-MPL).

114. A vaccine kit comprising an immunogenic composition according to any of claims 1 to 94 and further comprising for concomitant or sequential administration an adjuvant as defined in any of claims 96 to 113.

115. A vaccine comprising the immunogenic composition of any one of claims 1 to 113 and a pharmaceutically acceptable excipient.

116. A process for making the vaccine according to claim 116 which comprises the step of mixing the immunogenic composition of any of claims 1 to 113 with a pharmaceutically acceptable excipient.

117. A method of immunising a human host against disease caused by *Streptococcus pneumoniae* infection comprising administering to the host an immunoprotective dose of the immunogenic composition of any of claims 1 to 113 or vaccine of claim 115.

118. The method of claim 117, wherein the human host is elderly, and the disease is either or both of pneumonia or invasive pneumococcal disease (IPD).

119. The method of claim 117 or 118, wherein the human host is elderly, and the disease is exacerbations of chronic obstructive pulmonary disease (COPD).

120. The method of claim 117, wherein the human host is infant, and the disease is otitis media.

121. The method of claim 117 or 120, wherein the human host is infant, and the disease is meningitis and/or bacteraemia.

122. The method of claims 117, 120 or 121, wherein the human host is infant, and the disease is pneumonia and/or conjunctivitis.

123. The immunogenic composition of claims 1 to 113 or vaccine of claim 115 for use in the treatment or prevention of disease caused by *Streptococcus pneumoniae* infection.

124. A use of the immunogenic composition of claims 1 to 113 or vaccine of claim 115 in the manufacture of a medicament for the treatment or prevention of diseases caused by *Streptococcus pneumoniae* infection.

125. The use of claim 124, wherein the disease is either or both of pneumonia or invasive pneumococcal disease (IPD) of elderly humans.

126. The use of claim 124 or 125, wherein the disease is exacerbations of chronic obstructive pulmonary disease (COPD) of elderly humans.

127. The use of claim 124, wherein the disease is otitis media of infant humans.

128. The use of claim 124 or 127, wherein the disease is meningitis and/or bacteraemia of infant humans.

129. The use of claims 124, 127 or 128, wherein the disease is pneumonia and/or conjunctivitis of infant humans.

130. A use of the immunogenic composition of claims 1 to 113 or vaccine of claim 115 comprising a capsular saccharide conjugate of serotype 19F but not comprising capsular saccharide from serotype 19A in the manufacture of a medicament for the treatment or prevention of diseases caused by *Streptococcus pneumoniae* infection by serotype 19A strains.

131. A method of immunising a human host against disease caused by *Streptococcus pneumoniae* serotype 19A infection comprising the steps of administering to the host an immunoprotective dose of the immunogenic composition of claims 1 to 113 or vaccine of claim 115 which comprises a capsular saccharide conjugate of serotype 19F but does not comprise capsular saccharide from serotype 19A.

132. A method of eliciting a protective immune response in infants against Otitis media comprising the administration as separate or combined components, sequentially or concomitantly (i) an immunogenic composition or vaccine according to any of claims 1 to 115 and (ii) Protein D from *Haemophilus influenzae* which protein D may be free and/or conjugated.

133. A method of eliciting a protective immune response to infants against *S. pneumonia* by administering the immunogenic composition or vaccine of any preceding claim.

134. A method of eliciting a protective immune response to the elderly against *S. pneumonia* by administering in combination, sequentially or concomitantly (i) the immunogenic composition or vaccine of any preceding claim (ii) one or more *S. pneumoniae* surface proteins selected from the group consisting of the PhtX family and pneumolysin.

135. A method of eliciting a protective immune response to infants against Otitis media by administering the immunogenic composition or vaccine of any preceding claim.

136. A method of eliciting a protective immune response to the infants against Otitis media by administering as separate or combined components, sequentially or concomitantly (i) the vaccine of any preceding claim (ii) one or more *S. pneumoniae* surface proteins selected from the group consisting of the PhtX family and pneumolysin.

137. The immunogenic composition of claims 1-113 or vaccine of claim 115, which comprises saccharide conjugates derived from at least all the following serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 5, 7F wherein the GMC antibody titre induced against one or more of the vaccine components 4, 6B, 9V, 14, 18C, 19F and 23F is not significantly inferior to that induced by the Prevnar® vaccine in human vaccinees.

138. The immunogenic composition of claim 137, wherein the GMC antibody titre induced against serotype 4 is not significantly inferior to that induced by the Prevnar® vaccine in human vaccinees.

139. The immunogenic composition of claim 137 or 138, wherein the GMC antibody titre induced against serotype 6B is not significantly inferior to that induced by the Prevnar® vaccine in human vaccinees.

140. The immunogenic composition of claims 137-139, wherein the GMC antibody titre induced against serotype 9V is not significantly inferior to that induced by the Prevnar® vaccine in human vaccinees.

141. The immunogenic composition of claims 137-140, wherein the GMC antibody titre induced against serotype 14 is not significantly inferior to that induced by the Prevnar® vaccine in human vaccinees.

142. The immunogenic composition of claims 137-141, wherein the GMC antibody titre induced against serotype 18C is not significantly inferior to that induced by the Prevnar® vaccine in human vaccinees.

143. The immunogenic composition of claims 137-142, wherein the GMC antibody titre induced against serotype 19F is not significantly inferior to that induced by the Prevnar® vaccine in human vaccinees.

144. The immunogenic composition of claims 137-143, wherein the GMC antibody titre induced against serotype 23F is not significantly inferior to that induced by the Prevnar® vaccine in human vaccinees.

145. The immunogenic composition of claims 137-144 which comprises a serotype 3 saccharide conjugate.

146. The immunogenic composition of claims 137-145 which comprises a serotype 6A saccharide conjugate.

147. The immunogenic composition of claims 137-146 which comprises a serotype 19A saccharide conjugate.

148. The immunogenic composition of claims 137-147 which comprises a serotype 22F saccharide conjugate.